Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones
概述演示將回顧公司最近取得的一些成就以及對即將到來的數據里程碑的展望
JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
耶路撒冷，2024年12月11日（環球新聞專線）——創新型α-放射癌症療法Alpha Dart的開發商Alpha Tau Medical Ltd.（「Alpha Tau」 或 「公司」）（納斯達克股票代碼：DRTS，DRTSW）今天宣佈，首席執行官烏茲·索弗和首席財務官拉菲·利維將在1月16日星期四的摩根大通第43屆年度醫療保健會議上介紹公司概況和最新情況，2025年太平洋時間上午9點45分/美國東部時間下午 12:45，在加利福尼亞州舊金山舉行，並將在活動期間舉辦機構投資者會議。
| Event: | J.P. Morgan 43rd Annual Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 16, 2025 |
| Time: | 9:45AM PT – 10:25AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
| 活動： | 摩根大通第 43 屆年度醫療保健會議 |
| 格式： | 演講和一對一會議 |
| 日期： | 2025 年 1 月 16 日 |
| 時間： | 太平洋時間上午 9:45 — 太平洋時間上午 10:25 |
| 地點： | 加利福尼亞州舊金山聖弗朗西斯威斯汀酒店 |
Webcast: Link located on the "Events & Presentations" page in the Investor Relations section on the Company's website at
網絡直播：鏈接位於公司網站投資者關係部分的 「活動與演講」 頁面上
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
請聯繫您的摩根大通代表，安排與 Sofer 先生和 Levy 先生進行一對一的會面。
About Alpha Tau Medical Ltd.
關於 Alpha Tau 醫療有限公司
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha Tau成立於2016年，是一家以色列腫瘤治療公司，專注於實體瘤治療的Alpha dART的研究、開發和潛在商業化。該技術最初由特拉維夫大學的伊扎克·凱爾森教授和尤娜·凱薩里教授開發。
About Alpha DaRT
關於 Alpha Dart
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha dART（彌散型α-發射器放射療法）旨在通過在腫瘤內輸送浸過的鐳-224放射源，對實體瘤進行高效、隨形的α射線照射。當鐳衰變時，其短壽命的女兒會從源頭釋放並分散，同時發射出高能量的α粒子，目的是摧毀腫瘤。由於發射α的原子只能在很短的距離內擴散，因此Alpha Dart的目標是主要影響腫瘤，並保護腫瘤周圍的健康組織。
Investor Relations Contact:
IR@alphatau.com
投資者關係聯繫人：
IR@alphatau.com